Xencor, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company developing engineered antibody candidates for cancer, autoimmune disease and inflammatory disease. Its Form 8-K disclosures cover financial results, Regulation FD presentations for XmAb942, XmAb412 and the TL1A portfolio, royalty-related disclosures for Ultomiris, and material developments involving collaboration and license agreements.
Proxy materials describe board elections, executive compensation, equity-award information, stockholder voting matters and governance policies. Additional current reports address compensatory arrangements, including executive severance policy disclosures, alongside capital resources and operating-runway information furnished with financial updates.
Xencor, Inc. disclosed that Alexion Pharmaceuticals, the licensee for Ultomiris, has taken the position that it does not owe any additional royalties on U.S. sales of Ultomiris and does not intend to make future U.S. royalty payments under their Option and License Agreement. Alexion told Xencor it will continue paying royalties on sales outside the United States, and Xencor strongly disagrees with Alexion’s position and is evaluating its options.
Xencor had previously expected an estimated additional $100–$120 million in low single-digit U.S. Ultomiris royalties through 2028 based on a recently issued U.S. patent. Despite this potential loss of anticipated revenue, Xencor now expects to end 2026 with $380–$400 million in cash, cash equivalents and marketable debt securities and believes this will fund its research and operations into mid‑2028.
XNCR reported a Form 144 notice to sell of 6,758 common shares tied to restricted stock vesting on 03/02/2026. The filing shows these shares are held by Fidelity Brokerage Services LLC and are linked to compensation.
The excerpt also reports a prior disposition of 114,377 common shares by Bassil I. Dahiyat on 12/19/2025; the filing is a regulatory notice of proposed sales under the securities rules.
John Desjarlais filed a notice to sell 2,663 shares of common stock. The filing lists these shares as resulting from restricted stock vesting on 03/02/2026 and designates the transaction as compensation. The broker listed is Fidelity Brokerage Services LLC.
Separately, the filing discloses a prior sale of 73,367 shares on 12/19/2025 for $1,153,519.99, presented as securities sold during the past three months.
Xencor, Inc. filed an automatic shelf registration on Form S-3 to permit the sale from time to time of common stock, preferred stock, debt securities, warrants, rights, units and depositary shares "From time to time after the effective date of this Registration Statement".
The prospectus states the shelf has no limit on aggregate amount and that specific offering terms will be provided in prospectus supplements; it notes 71,871,975 shares of common stock outstanding as of December 31, 2025 and a last reported sale price of $11.57 per share on February 23, 2026.
Xencor, Inc. uses its XmAb protein engineering platforms to develop bispecific and engineered antibody therapies for cancer and autoimmune diseases. The company focuses on Fc-domain technologies that extend half-life, enhance cytotoxicity, and enable multi-target mechanisms, and advances select candidates itself while out-licensing others.
Xencor’s wholly owned clinical pipeline includes oncology candidates XmAb819 and XmAb541, CD28 bispecific XmAb808, anti-TL1A antibody XmAb942 for inflammatory bowel disease, plamotamab for rheumatoid arthritis, and XmAb657 for idiopathic inflammatory myopathies. In 2025 it advanced multiple Phase 1 and 2 trials, initiated new proof‑of‑concept autoimmune studies, and selected XmAb412 as a lead TL1A x IL23p19 bispecific.
The company also earns milestone and royalty revenue from partners. Alexion’s Ultomiris®, which uses Xencor’s Xtend Fc technology, generated an estimated non‑cash royalty of $70.1 million in 2025, while Incyte’s Monjuvi® contributed $10.2 million. Additional partnered programs with Amgen, Astellas, Janssen, Vir, Zenas and others broaden Xencor’s exposure across oncology, autoimmune and infectious disease indications.
Xencor reported 2025 results showing higher revenue and a much smaller loss while advancing a broad pipeline. Full-year revenue rose to $125.6 million from $110.5 million, driven mainly by Alexion and Incyte license revenue. Net loss attributable to Xencor narrowed to $91.9 million, or $(1.24) per share, from $232.6 million, or $(3.58) per share.
Cash, cash equivalents and marketable debt securities totaled $610.8 million as of December 31, 2025, and the company expects to end 2026 with $400–$430 million, funding operations through 2028. Xencor highlighted multiple clinical programs, including Phase 1 dose expansion for lead oncology asset XmAb819 and progress across its TL1A inflammatory bowel disease portfolio, with several data presentations and potential pivotal-study decisions planned in 2026–2027.
The company also noted a U.S. patent term extension for its Xtend Fc domain used in Ultomiris, and estimates potential royalty revenue of $100–$120 million in aggregate over the extended period through 2028.
EcoR1 Capital and related parties report a sizable passive stake in Xencor Inc. EcoR1 Capital, LLC and Oleg Nodelman each report beneficial ownership of 4,640,000 Xencor common shares, representing 6.4% of the class, including both common stock and warrants. EcoR1 Capital Fund Qualified, L.P. reports beneficial ownership of 4,354,981 shares, or 6.0% of the class. These percentages are based on 71,410,469 common shares outstanding as of October 30, 2025, as cited from Xencor’s Form 10‑Q. The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Xencor.
BVF Partners and affiliated funds report a significant passive stake in Xencor Inc. As of December 31, 2025, Biotechnology Value Fund, BVF2 and Biotechnology Value Trading Fund OS together beneficially owned 7,133,720 shares of Xencor common stock. This represents approximately 9.99% of the 71,410,469 shares outstanding as of October 30, 2025.
Individually, BVF held 3,798,627 shares (about 5.3% of the class) and BVF2 held 2,787,735 shares (about 3.9%), with additional shares held by Trading Fund OS and a Partners managed account. The filing is signed by Mark N. Lampert, who may be deemed to share beneficial ownership through various BVF entities.
The reporting group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Xencor, indicating a passive investment stance under Schedule 13G.
State Street Corporation has filed a Schedule 13G reporting a passive ownership stake in Xencor Inc. common stock. As of the event date of 12/31/2025, State Street reports beneficial ownership of 4,507,254 shares, representing 6.3% of Xencor’s outstanding common stock.
State Street reports no sole voting or dispositive power, with 4,308,425 shares under shared voting power and 4,507,254 shares under shared dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Xencor.